BIVA and VExUS for hydration assessment and cardiovascular mortality prediction in cardiorenal patients
- 29 May 2026
- journal article
- Published by IOP Publishing in Physiological Measurement
- Vol. 47 (5) , 055023
Abstract
Objectives . Despite advances in pharmacological treatment, heart failure (HF) remains a leading cause of hospitalization, mortality, and healthcare costs. HF often coexists with chronic kidney disease (CKD), impacting diagnosis, prognosis, and treatment. This study aims to evaluate correlations between bioelectrical impedance vector analysis (BIVA), ultrasound via VExUS, biomarkers (Ca125), and clinical outcomes assessing congestion and predicting cardiovascular mortality in patients with cardiorenal syndrome (CRS). Approach . This prospective observational study included 85 patients with HF and CKD assessed at the Endocardiorenal Unit of Virgen de la Victoria University Hospital. Patients underwent a comprehensive evaluation including BIVA (AKERN BIA 101 BIVA® device), ultrasound assessment (General Electric Vivid T8 system device) for VexUS evaluation, and biomarkers (Ca125, NT-proBNP). BIVA measurements were taken using a 50 kHz phase-sensitive impedance analyzer to measure resistance ( R ) and reactance ( X c). Statistical analysis involved Pearson’s correlation and Cox regression to determine the relationships between these methods and mortality risk. Main results . Among the 85 patients (mean age 75.2 ± 8.4 years, 58.8% men), 11 cardiovascular and 8 non-cardiovascular deaths occurred over a 12-month follow-up. Strong statistically significant association was found between age, low hemoglobin levels, NYHA dyspnea, and mortality. Moderate statistically significant association was observed between BIVA hydration (HYDRAGRAM® calculated by device) and VExUS ( r = 0.51, p < 0.001), with a hydration cut-off point of 78.7% predicting cardiovascular mortality. There was also a significant association between reactance ( p = 0.03) and phase angle (PhA) ( p = 0.006) with mortality. Cox regression analysis showed that patients with higher hydration had 5.43 times the risk of mortality compared to those with lower hydration (HR = 5.43, 95% CI: 1.36-21.61, p = 0.016). Significance . Integrating BIVA, VExUS, and Ca125 effectively assesses congestion in CRS patients. A BIVA-derived hydration threshold >78.7% was independently associated with 12-month cardiovascular mortality, supporting its value for risk stratification and improving patient management.Keywords
Funding Information
- AstraZeneca
This publication has 47 references indexed in Scilit:
- Biomarkers of Hemodynamic Congestion in Heart FailureCurrent Heart Failure Reports, 2024
- Investigating the Relationship Between Frailty and Quality of Life in Patients with Heart Failure and CKD (FRAIL Study)ESC Heart Failure, 2024
- The treatment of chronic anemia in heart failure: a global approachClinical Research in Cardiology, 2023
- The role of bioelectrical phase angle in patients with heart failureReviews in Endocrine and Metabolic Disorders, 2022
- Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of CardiologyEuropean Journal of Heart Failure, 2022
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Journal of Heart Failure, 2022
- Antigen carbohydrate 125 as a biomarker in heart failure: a narrative reviewEuropean Journal of Heart Failure, 2021
- Co-Morbidities in Patients with Heart Failure: An Analysis of the European Heart Failure Pilot SurveyEuropean Journal of Heart Failure, 2013
- International evidence-based recommendations for point-of-care lung ultrasoundIntensive Care Medicine, 2012
- Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levelsHeart Failure Reviews, 2011